Restoration of Haemopoietic Function in the Irradiated Mouse by Means of Allogeneic Bone‐Marrow Grafts from Several Donors of Different Strains*

Mathé, G; Amiel, J. L.; Matsukura, Makoto; Méry, A. M.

doi:10.1111/j.1365-2141.1964.tb00700.x

Cited by 9 publications

(2 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Numerous studies have investigated the influence of various interventions on incidence and severity of GVHD. Incidence is clearly re lated to histocompatibility [15,20,25], severity, as measured by survival, can be influenced by MTX [14,18,24,27]. A major problem confront ing human transplantation is that no assay is available which will predict the development of GVHD and therefore identify the patient who possi bly requires the most vigorous intervention with immunosuppression.…”

Section: Discussionmentioning

confidence: 99%

“…Matching of donor and recipient at the major histocompatibility locus re duces severity and incidence of GVHD in rodents, dogs and man [15,20,25]. Posttransplantation immunosuppression by drugs has been investi gated as an additional approach [5,16,21,25,29], Methotrexate (MTX) was shown to increase posttransplantation survival in mice and dogs [24,27] if given early after transplantation and on a prolonged schedule [14,18].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Methotrexate and Citrovorum Factor after Histoincompatible Allogeneic Bone Marrow Transplants in Dogs

Gratwohl¹,

Bull²,

Graw³

et al. 1978

Acta Haematol

View full text Add to dashboard Cite

Methotrexate (MTX) followed by citrovorum factor (CVF) rescue was evaluated for its effectiveness in reducing graft-versus-host disease (GVHD) in lethally irradiated dogs transplanted with bone marrow from unrelated histoincompatible donors. Animals were given no immunosuppressive therapy (group A) or a combined regimen of MTX and CVF (group AMC). These two groups were compared with a group of animals transplanted earlier given MTX alone (group AM). Animals in the AMC group lived significantly longer than the A group (p < 0.05). Engraftment rate, hematopoietic recovery and incidence of GVHD were similar in all three groups. Incidence of early deaths was significant in the AM group (p < 0.05). It is concluded that MTX combined with CVF increases survival and is an effective posttransplantation immunosuppressive regimen with minimal toxicity.

show abstract